N
NYMX

Nuveen’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Nuveen’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-153,866
Closed -$341K – 3586
2021
Q1 		$341K Sell
153,866
-3,468
-2% -$9.14K ﹤0.01% 3151
2020
Q4 		$390K Buy
157,334
+1,839
+1% +$4.06K ﹤0.01% 3093
2020
Q3 		$382K Sell
155,495
-18
-0% -$52 ﹤0.01% 3026
2020
Q2 		$552K Buy
+155,513
New +$492K ﹤0.01% 2860

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.7B AUM 31.52% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Nuveen's NYMX Position: Q2 2021 in Review

Nuveen sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2021, closing a stake of 153,866 shares — an estimated $341K sold.

Nuveen first reported a position in NYMX in Q2 2020 and held it in 4 quarters. The position peaked at $552K in Q2 2020. 51 funds tracked by Wall St. Rank hold NYMX as of Q2 2021.

  • Nuveen reported no remaining Nymox Pharmaceutical Corp position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 153,866 Nymox Pharmaceutical Corp shares in Q2 2021, an estimated $341K.
  • Nuveen first reported a position in Nymox Pharmaceutical Corp in Q2 2020 and held it in 4 quarters.
  • Nuveen's Nymox Pharmaceutical Corp position peaked at $552K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.